- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Idelalisib, Rituximab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin (9-39), Vehicle
- Drug
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Multiple Sclerosis Center of Northeastern New York
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Nutrition, Health, Dietary Habits
- Interventions
- Diet A, Diet B, Diet C
- Other
- Lead sponsor
- RTI International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Davis, California • Los Angeles, California + 7 more
- Conditions
- Advanced Cancer
- Interventions
- Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 57
- States / cities
- Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis
- Interventions
- N-Acetylcysteine
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Irvine, California • Orange, California
- Conditions
- Electrocardiography
- Interventions
- Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Trauma Injury
- Interventions
- Immunofluorescence Imaging, DCE-MRI
- Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Irvine, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Houston, Texas
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Cardiopulmonary Bypass
- Interventions
- Coagulation function
- Device
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma
- Interventions
- NC318
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Resectable Head and Neck Squamous-cell Carcinoma
- Interventions
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM, PD-1 inhibitor monotherapy - 2 cycles after 3 PM
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Blood Sample Collection - Observational Study, Symptom questionnaires - Observational Study
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- Copanlisib, Ibrutinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- Interventions
- Ezabenlimab, BI 754111, BI 836880
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 11
- States / cities
- La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more
- Conditions
- Anaemia
- Interventions
- GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Colitis, Ulcerative
- Interventions
- placebo, MultiStem low dose, MultiStem high dose
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 37
- States / cities
- San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis, (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis
- Combination Product
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- COVID-19
- Interventions
- hAd5-S-Fusion+N-ETSD vaccine
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- El Segundo, California • Newport Beach, California
- Conditions
- Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Interventions
- Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery
- Procedure · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more
- Conditions
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Interventions
- TAK-007, Chemotherapy Agents
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Zanubrutinib, Bendamustine, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 18
- States / cities
- Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin, Ranolazine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida